Literature DB >> 25288484

Using cluster analysis to identify phenotypes and validation of mortality in men with COPD.

Chiung-Zuei Chen1, Liang-Yi Wang, Chih-Ying Ou, Cheng-Hung Lee, Chien-Chung Lin, Tzuen-Ren Hsiue.   

Abstract

PURPOSE: Cluster analysis has been proposed to examine phenotypic heterogeneity in chronic obstructive pulmonary disease (COPD). The aim of this study was to use cluster analysis to define COPD phenotypes and validate them by assessing their relationship with mortality.
METHODS: Male subjects with COPD were recruited to identify and validate COPD phenotypes. Seven variables were assessed for their relevance to COPD, age, FEV(1) % predicted, BMI, history of severe exacerbations, mMRC, SpO(2), and Charlson index. COPD groups were identified by cluster analysis and validated prospectively against mortality during a 4-year follow-up.
RESULTS: Analysis of 332 COPD subjects identified five clusters from cluster A to cluster E. Assessment of the predictive validity of these clusters of COPD showed that cluster E patients had higher all cause mortality (HR 18.3, p < 0.0001), and respiratory cause mortality (HR 21.5, p < 0.0001) than those in the other four groups. Cluster E patients also had higher all cause mortality (HR 14.3, p = 0.0002) and respiratory cause mortality (HR 10.1, p = 0.0013) than patients in cluster D alone.
CONCLUSION: COPD patient with severe airflow limitation, many symptoms, and a history of frequent severe exacerbations was a novel and distinct clinical phenotype predicting mortality in men with COPD.

Entities:  

Mesh:

Year:  2014        PMID: 25288484     DOI: 10.1007/s00408-014-9646-x

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  33 in total

Review 1.  Multi-dimensional phenotyping: towards a new taxonomy for airway disease.

Authors:  A J Wardlaw; M Silverman; R Siva; I D Pavord; R Green
Journal:  Clin Exp Allergy       Date:  2005-10       Impact factor: 5.018

2.  Case definitions for chronic obstructive pulmonary disease.

Authors:  Eva Hnizdo; Henry W Glindmeyer; Edward L Petsonk; Paul Enright; A Sonia Buist
Journal:  COPD       Date:  2006-06       Impact factor: 2.409

3.  Mortality by level of emphysema and airway wall thickness.

Authors:  Ane Johannessen; Trude Duelien Skorge; Matteo Bottai; Thomas Blix Grydeland; Roy Miodini Nilsen; Harvey Coxson; Asger Dirksen; Ernst Omenaas; Amund Gulsvik; Per Bakke
Journal:  Am J Respir Crit Care Med       Date:  2013-01-17       Impact factor: 21.405

4.  Clinical COPD phenotypes identified by cluster analysis: validation with mortality.

Authors:  Pierre-Régis Burgel; Nicolas Roche; Jean-Louis Paillasseur; Isabelle Tillie-Leblond; Pascal Chanez; Roger Escamilla; Isabelle Court-Fortune; Thierry Perez; Philippe Carré; Denis Caillaud
Journal:  Eur Respir J       Date:  2012-08       Impact factor: 16.671

5.  Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.

Authors:  J J Soler-Cataluña; M A Martínez-García; P Román Sánchez; E Salcedo; M Navarro; R Ochando
Journal:  Thorax       Date:  2005-07-29       Impact factor: 9.139

6.  Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease.

Authors:  R Antonelli Incalzi; L Fuso; M De Rosa; F Forastiere; E Rapiti; B Nardecchia; R Pistelli
Journal:  Eur Respir J       Date:  1997-12       Impact factor: 16.671

Review 7.  Mortality in COPD: Role of comorbidities.

Authors:  D D Sin; N R Anthonisen; J B Soriano; A G Agusti
Journal:  Eur Respir J       Date:  2006-12       Impact factor: 16.671

Review 8.  Exacerbations in chronic obstructive pulmonary disease: do they contribute to disease progression?

Authors:  Edwin K Silverman
Journal:  Proc Am Thorac Soc       Date:  2007-12

9.  Cluster analysis and clinical asthma phenotypes.

Authors:  Pranab Haldar; Ian D Pavord; Ruth H Green; Dominic E Shaw; Michael A Berry; Michael Thomas; Christopher E Brightling; Andrew J Wardlaw
Journal:  Am J Respir Crit Care Med       Date:  2008-05-14       Impact factor: 21.405

Review 10.  COPD exacerbations: defining their cause and prevention.

Authors:  Jadwiga A Wedzicha; Terence A R Seemungal
Journal:  Lancet       Date:  2007-09-01       Impact factor: 79.321

View more
  6 in total

1.  Identification of Phenotypes in People with COPD: Influence of Physical Activity, Sedentary Behaviour, Body Composition and Skeletal Muscle Strength.

Authors:  Rafaella F Xavier; Ana Carolina A C Pereira; Aline C Lopes; Vinícius Cavalheri; Regina M C Pinto; Alberto Cukier; Ercy M C Ramos; Celso R F Carvalho
Journal:  Lung       Date:  2018-11-14       Impact factor: 2.584

2.  Applying Machine Learning Algorithms to Segment High-Cost Patient Populations.

Authors:  Jiali Yan; Kristin A Linn; Brian W Powers; Jingsan Zhu; Sachin H Jain; Jennifer L Kowalski; Amol S Navathe
Journal:  J Gen Intern Med       Date:  2018-12-12       Impact factor: 5.128

3.  Cluster Analysis of Obesity Disease Based on Comorbidities Extracted from Clinical Notes.

Authors:  Ruth Reátegui; Sylvie Ratté; Estefanía Bautista-Valarezo; Víctor Duque
Journal:  J Med Syst       Date:  2019-01-28       Impact factor: 4.460

4.  Distinct symptom experiences in subgroups of patients with COPD.

Authors:  Vivi L Christensen; Tone Rustøen; Bruce A Cooper; Christine Miaskowski; Anne H Henriksen; Signe B Bentsen; Are M Holm
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-08-02

5.  Classification and characterization of class III malocclusion in Chinese individuals.

Authors:  Cai Li; Ying Cai; Sihui Chen; Fengshan Chen
Journal:  Head Face Med       Date:  2016-11-07       Impact factor: 2.151

6.  Proteoglycan 4 is a diagnostic biomarker for COPD.

Authors:  Kang-Yun Lee; Hsiao-Chi Chuang; Tzu-Tao Chen; Wen-Te Liu; Chien-Ling Su; Po-Hao Feng; Ling-Ling Chiang; Mauo-Ying Bien; Shu-Chuan Ho
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-09-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.